Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

IBT's Ailsa Craig and Marek Poszepczynski give their key stock picks as companies move on from the science to commercial ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Alumis Inc., a San Francisco-based biotech, completed its IPO in June last year, raising ~$250m, and focuses on developing TYK2 inhibitors ESK-001 and A-005. Alumis' ESK-001 is in Phase 3 trials for ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

Shares of IO Biotech, Inc. IOBT are plummeting Tuesday after the company announced it filed for Chapter 7 bankruptcy and will ...